This page was created by volunteers like you!
Help us make it even better. To learn more about contributing to MEpedia, click here.
Join the movement
Visit #MEAction to find support or take action. Donate today to help us improve and expand this project.
Congratulations!
MEpedia has got over 30 million views as of August 2022!

Cancer

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

This article contains information on cancer in people with ME/CFS, and the the use of drugs developed for cancer in people with ME/CFS.

For information about post-cancer fatigue, see cancer-related fatigue.

Signs and symptoms[edit | edit source]

Treatment[edit | edit source]

In isolated cases, certain ME/CFS patients undergoing cancer treatment found that their ME/CFS symptoms improved. This has led to clinical trials of a few specific cancer ME/CFS drugs.[1]

ME/CFS[edit | edit source]

A study by Chang et al. (2012) found that a history of chronic fatigue syndrome was associated with an increased risk of certain Non-Hodgkin lymphomas, specifically diffuse large B cell lymphoma, marginal zone lymphoma, and B cell Non-Hodgkin lymphoma not otherwise specified.[2]

Ampligen[edit | edit source]

Ampligen (rintatolimod) is an unlicensed, experimental drug originally developed for cancer.

Cyclophosphamide[edit | edit source]

An observational study of ME/CFS patients with cancer who were prescribed cyclophosphamide for their cancers, showed unexpected improvements in ME/CFS symptoms.[1]

Rituximab[edit | edit source]

Rituximab, a drug used for leukemia,[3] has been through several clinical trials for ME/CFS patients, but failed in a phase III clinical trial.[citation needed]

Notable studies[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. Jump up to: 1.0 1.1 1.2 Rekeland, Ingrid G.; Fosså, Alexander; Lande, Asgeir; Ktoridou-Valen, Irini; Sørland, Kari; Holsen, Mari; Tronstad, Karl J.; Risa, Kristin; Alme, Kine; Viken, Marte K.; Lie, Benedicte K.; Dahl, Olav; Mella, Olav; Fluge, Øystein (2020). "Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study". Frontiers in Medicine. 7: 162. doi:10.3389/fmed.2020.00162. ISSN 2296-858X. PMC 7201056. PMID 32411717.
  2. Jump up to: 2.0 2.1 Chang, C.M.; Warren, J.L.; Engels, E.A. (2012). "Chronic fatigue syndrome and subsequent risk of cancer among elderly U.S. adults". Cancer. 118 (23): 5929–5936. doi:10.1002/cncr.27612.
  3. https://www.cancer.gov/about-cancer/treatment/drugs/rituximab
  4. McManimen, Stephanie L.; Devendorf, Andrew R.; Brown, Abigail A.; Moore, Billie C.; Moore, James H.; Jason, Leonard A. (2016). "Mortality in patients with myalgic encephalomyelitis and chronic fatigue syndrome". Fatigue: Biomedicine, Health & Behavior. 4 (4): 195–207. doi:10.1080/21641846.2016.1236588.
  5. https://ajbm.net/bm-publisher-5711-2/
  6. Levine, Paul H.; Pilkington, Deborah; Strickland, Paula; Peterson, Daniel (2000). "Chronic Fatigue Syndrome and Cancer". Journal of Chronic Fatigue Syndrome. 7 (1): 29–38. doi:10.1300/J092v07n01_04.